成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 366789-02-8 Chemical Structure| 366789-02-8
Chemical Structure| 366789-02-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 366789-02-8

,{[proInfo.pro_purity]}

Rivaroxaban is an inhibitor of factor Xa (FXa) with IC50 of 0.7 nM and Ki of 0.4 nM which developed for the treatment of thrombotic disease.

Synonyms: BAY 59-7939

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Product Citations      Show More

Patrick Opitz ; Isabel Waltering ; Georg Hempel ;

Abstract: The number of prescriptions for new direct oral anticoagulants (DOACs) apixaban, edoxaban, rivaroxaban and dabigatran has increased exponentially in recent years, increasingly replacing the old gold standard, vitamin-K-antagonists. Due to their wide therapeutic range, therapeutic drug monitoring (TDM) is not required, although it has been proven that this could significantly reduce side effects. In order to develop a cost-efficient and simple method for the simultaneous detection of the DOACs and phenprocoumon, a new technology for sample preparation from capillary blood in the ambulant sector named VAMS? was integrated and an LC-MS detector with on-line solid phase extraction (SPE) applying a Turboflow HTLC CycloneTM 1.0x50 mm column was used. The mobile phase consisted of methanol with water (3/97 v/v) and 0.1% ammonia solution with a flow rate of 2.5 mL/min. For the chromatographic separation, a Phenomenex LTD Kinetex 2.6 μm C18 100 ?, 100x3.0 mm column with a flow rate of 0.3 mL/min in gradient mode was utilized. The mobile phase consisted of acetonitrile, water and formic acid (A: 10:90:0.1 v/v and B: 95:05:0.1 v/v). The method was fully validated in the therapeutic range of the substances according to current guidelines. The LLOQ ranged from 3.5 μg/L for rivaroxaban to 88 μg/L for phenprocoumon and the intra-day and inter-day precision was less than 13% and 12%, while the accuracy was within a range of 85.7-113% and 88.7-106%, respectively. Samples could be stored in the mitra? devices for at least seven days at room temperature except of dabigatran. Because the mitras? were used, no significant haematocrit effect could be observed. A reliable, simple and cost-effective extraction and analysis LC-MS method could be developed and validated. This method is therefore applicable in ambulatory care.

Keywords: therapeutic drug monitoring (TDM) ; anticoagulant ; volumetric absorptive microsampling (VAMS) ; LC-MS ; Validation ; On-line solid phase extraction (SPE)

Purchased from AmBeed:

Marino-Ocampo, Nory ; Rodriguez, Diego F. ; Guerra Diaz, Daniel ; Zuniga-Nunez, Daniel ; Duarte, Yorley ; Fuentealba, Denis , et al.

Abstract: Direct FXa inhibitors are an important class of bioactive mols. (rivaroxaban, apixaban, edoxaban, and betrixaban) applied for thromboprophylaxis in diverse cardiovascular pathologies. The interaction of active compounds with human serum albumin (HSA), the most abundant protein in blood plasma, is a key research area and provides crucial information about drugs' pharmacokinetics and pharmacodynamic properties. This research focuses on the study of the interactions between HSA and four com. available direct oral FXa inhibitors, applying methodologies including steady-state and time-resolved fluorescence, isothermal titration calorimetry (ITC), and mol. dynamics. The HSA complexation of FXa inhibitors was found to occur via static quenching, and the complex formation in the ground states affects the fluorescence of HSA, with a moderate binding constant of 104 M-1. However, the ITC studies reported significantly different binding constants (103 M-1) compared with the results obtained through spectrophotometric methods. The suspected binding mode is supported by mol. dynamics simulations, where the predominant interactions were hydrogen bonds and hydrophobic interactions (mainly π-π stacking interactions between the Ph ring of FXa inhibitors and the indole moiety of Trp214). Finally, the possible implications of the obtained results regarding pathologies such as hypoalbuminemia are briefly discussed.

Keywords: FXa inhibitors ; human serum albumin ; fluorescence ; isothermal titration calorimetry ; molecular modeling ; direct oral FXa inhibitors ; commercially available FXa inhibitors ; apixaban ; rivaroxaban ; edoxaban ; betrixaban

Purchased from AmBeed: ; ;

Alternative Products

Product Details of Rivaroxaban

CAS No. :366789-02-8
Formula : C19H18ClN3O5S
M.W : 435.88
SMILES Code : O=C(C1=CC=C(Cl)S1)NC[C@H]2CN(C3=CC=C(N4C(COCC4)=O)C=C3)C(O2)=O
Synonyms :
BAY 59-7939
MDL No. :MFCD11974010

Safety of Rivaroxaban

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H318-H411
Precautionary Statements:P280-P305+P351+P338+P310
Class:9
UN#:3077
Packing Group:Ⅲ
 

Related Products

Historical Records

Categories